New drug IB-001 enters first human tests for chronic hepatitis b
NCT ID NCT07389044
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This early-stage study tests a new drug called IB-001 for chronic hepatitis B. It will first check safety in up to 60 healthy volunteers, then test multiple doses in about 30 people with chronic hepatitis B. The main goal is to see if the drug is safe and how the body handles it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arensia Exploratory Medicine Chisinau
RECRUITINGChisinau, 2025, Moldova
-
New Zealand Clinical Research
RECRUITINGAuckland, 1010, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo aims to cure chronic hepatitis b
- New injection aims to tame chronic hepatitis b
- Zambia study tracks hepatitis b outcomes in hundreds of patients
- New drug cocktail shows promise for liver cancer in hepatitis b patients
- New shot aims to tame hepatitis b virus
- New hepatitis b drug shows early promise in small trial